Q1 Earnings Estimate for Immunovant Issued By Zacks Research

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Stock analysts at Zacks Research cut their Q1 2026 EPS estimates for Immunovant in a research note issued to investors on Tuesday, January 7th. Zacks Research analyst E. Bagri now forecasts that the company will earn ($0.82) per share for the quarter, down from their previous forecast of ($0.79). The consensus estimate for Immunovant's current full-year earnings is ($2.73) per share. Zacks Research also issued estimates for Immunovant's Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.38) EPS, Q1 2027 earnings at ($0.87) EPS, Q2 2027 earnings at ($0.95) EPS, Q3 2027 earnings at ($0.90) EPS and FY2027 earnings at ($3.63) EPS.

Other analysts have also issued research reports about the stock. Raymond James reiterated an "outperform" rating and set a $36.00 target price on shares of Immunovant in a research note on Thursday, October 10th. HC Wainwright restated a "buy" rating and set a $51.00 price target on shares of Immunovant in a research report on Friday, November 8th. Wolfe Research lowered shares of Immunovant from an "outperform" rating to a "peer perform" rating in a research report on Friday, January 3rd. Wells Fargo & Company lowered their price target on shares of Immunovant from $47.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, December 19th. Finally, Oppenheimer upped their price target on shares of Immunovant from $47.00 to $53.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, Immunovant presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.22.

Immunovant Stock Down 0.6 %

IMVT stock traded down $0.15 during trading on Friday, hitting $23.48. 832,137 shares of the company's stock traded hands, compared to its average volume of 685,890. Immunovant has a 52 week low of $23.08 and a 52 week high of $43.92. The stock has a fifty day moving average price of $27.07 and a two-hundred day moving average price of $28.58. The stock has a market capitalization of $3.45 billion, a price-to-earnings ratio of -10.58 and a beta of 0.66.

Immunovant (NASDAQ:IMVT - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). During the same quarter in the previous year, the company posted ($0.45) EPS.

Institutional Trading of Immunovant

A number of hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in Immunovant by 69.9% during the third quarter. Principal Financial Group Inc. now owns 951,124 shares of the company's stock valued at $27,117,000 after buying an additional 391,436 shares in the last quarter. Tyro Capital Management LLC lifted its position in shares of Immunovant by 0.6% in the third quarter. Tyro Capital Management LLC now owns 252,149 shares of the company's stock worth $7,189,000 after purchasing an additional 1,529 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Immunovant by 6.9% in the third quarter. Geode Capital Management LLC now owns 1,510,926 shares of the company's stock worth $43,085,000 after purchasing an additional 96,924 shares in the last quarter. State Street Corp lifted its position in shares of Immunovant by 11.2% in the third quarter. State Street Corp now owns 3,022,342 shares of the company's stock worth $86,167,000 after purchasing an additional 303,386 shares in the last quarter. Finally, Baker BROS. Advisors LP lifted its position in shares of Immunovant by 163.7% in the third quarter. Baker BROS. Advisors LP now owns 1,225,410 shares of the company's stock worth $34,936,000 after purchasing an additional 760,692 shares in the last quarter. 47.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Immunovant

In other Immunovant news, CFO Eva Renee Barnett sold 3,271 shares of the company's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $28.79, for a total transaction of $94,172.09. Following the completion of the sale, the chief financial officer now directly owns 335,343 shares of the company's stock, valued at approximately $9,654,524.97. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William L. Macias sold 3,188 shares of the company's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $28.79, for a total transaction of $91,782.52. Following the sale, the insider now directly owns 365,144 shares of the company's stock, valued at $10,512,495.76. This represents a 0.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 77,247 shares of company stock valued at $2,034,425. 5.90% of the stock is owned by insiders.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.